JNCE - Jounce Therapeutics, Inc.
| Previous Close | 5.83 |
| Open | 5.86 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 5.45 - 6.01 |
| 52 Week Range | 5.43 - 29.25 |
| Volume | 232,266 |
| Avg. Volume | 281,756 |
| Market Cap | 182.062M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings Date | Aug 9, 2018 - Aug 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.75 |
- GlobeNewswire•3 days ago
New Research Coverage Highlights Himax Technologies, Corporacion America Airports S.A, Tecnoglass, Jounce Therapeutics, Hollysys Automation Technologies, and Obsidian Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•21 days ago
Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that its scientific founder, Dr. James P. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine for the discovery of cancer therapy by inhibition of negative immune regulation. Since our founding, Jounce has benefited tremendously from his leadership, expertise and dedication to cancer immunotherapy and this award is a testament to all that he has accomplished,” said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. “Jim played a fundamental role in ushering in the era of cancer immunotherapy, including his contributions to the understanding of the basic science of CTLA-4.
- GlobeNewswire•26 days ago
Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 26, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
- GlobeNewswire•2 months ago
Jounce Therapeutics to Present at Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 29, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alamos ...
- Zacks•2 months ago
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire•2 months ago
Jounce Therapeutics Reports Second Quarter 2018 Financial Results
-Initiated enrollment in dose escalation cohorts of Phase 1/ 2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab-. -Presented preliminary efficacy data for ...
- ACCESSWIRE•2 months ago
Jounce Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: JNCE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
- GlobeNewswire•3 months ago
Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
CAMBRIDGE, Mass., Aug. 02, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
- ACCESSWIRE•3 months ago
Free Technical Research on Intrexon and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
- InvestorPlace•5 months ago
Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
- ACCESSWIRE•5 months ago
Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...
- Motley Fool•5 months ago
Here's Why Jounce Therapeutics Fell Over 38% Today
The early-stage company's lead drug candidate disappointed in a phase 1/2 study.
- SmarterAnalyst•5 months ago
Recent Sell-Off in Jounce therapeutics’ (JNCE) Stock Is Unwarranted
In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took a significant haircut, but was the drop justified? The goal of the therapy is to tip the balance between these two subtypes of T-cells towards the effector cells by depleting T-regs through antibody activity (ADCC) and encouraging growth of T-effector cells which express ICOS.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...
- Motley Fool•5 months ago
Jounce Therapeutics Gets Throttled, Loses 35% Today
The clinical-stage upstart reported disappointing news that sparked pessimism.
- Motley Fool•5 months ago
Why J.C. Penney, NetEase, and Jounce Therapeutics Slumped Today
Find out which of these stocks fell because of earnings concerns.
- Benzinga•5 months ago
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
Wells Fargo Securities analyst Jim Birchenough downgraded Jounce from Outperform to Market Perform and lowered the price target from $37 to $13. The overall response rate for JTX-2011 as a monotherapy in gastric cancer and triple negative breast cancer, and for the JTX-2011-Opdivo combo in gastric cancer and TNBC, is underwhelming, Birchenough said in a Thursday note.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMT
Q1 2018 Jounce Therapeutics Inc Earnings Call
